ZVRA

Business Context and Reporting Period

Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage biopharmaceutical company focused on rare diseases. This Form 10-Q covers the quarterly period ended September 30, 2024. The company recently received FDA approval for MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on September 20, 2024, and continues to commercialize OLPRUVA for urea cycle disorders. Zevra also maintains a pipeline including celiprolol for Vascular Ehlers-Danlos syndrome and KP1077 for idiopathic hypersomnia.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Q3 2024 revenue increased by $0.8 million compared to Q3 2023, driven by higher royalties from the AZSTARYS license and French Expanded Access Program (EAP) reimbursements. However, 9-month revenue decreased by $3.0 million due to the absence of a $5.0 million sales milestone recognized in 2023.
• Net Loss: Net loss widened significantly in Q3 2024 ($33.2 million vs. $10.4 million) and for the 9-month period ($69.8 million vs. $26.2 million). This was primarily due to increased operating expenses (SG&A up $10.4 million in Q3) and a $4.7 million loss from fair value adjustments on warrant liabilities.
• Debt Structure: In April 2024, the company entered a new $100 million senior secured credit facility, funding $60 million initially. This replaced a $37.7 million line of credit and a $5.0 million promissory note, both of which were repaid in April 2024.
• Equity Financing: In August 2024, Zevra completed a public offering of approximately 10.6 million shares, raising net proceeds of approximately $64.5 million.
• Inventory: The company recognized a $5.2 million inventory obsolescence charge in the first nine months of 2024, compared to none in the prior year.

Guidance, Outlook, and Risks

• Going Concern: Management states that recurring operating losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Continued operations depend on generating revenue from approved products or securing additional financing.
• Liquidity Outlook: Based on the August 2024 offering proceeds and existing cash, management believes resources are sufficient to fund operations into 2027, subject to compliance with debt covenants.
• Commercialization: The company is in the early stages of commercializing MIPLYFFA and OLPRUVA. MIPLYFFA received a transferable Rare Pediatric Disease Priority Review Voucher (PRV) upon approval.
• Legal Proceedings: A dispute has arisen with Commave Therapeutics regarding the AZSTARYS License Agreement. Commave filed a complaint in September 2024 alleging breach of contract. Zevra has filed a motion to dismiss and expects significant legal expenses.
• Debt Covenants: The new credit agreement requires maintaining a minimum cash balance of $20.0 million and meeting minimum net product sales amounts.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $95.5 million in total liquid assets (cash + investments) against the burn rate and debt service requirements through 2027.
• Debt Covenants: Monitor compliance with the $20 million minimum cash balance covenant and minimum net product sales thresholds under the new $100 million credit facility.
• Commercial Execution: Track early sales data for MIPLYFFA and OLPRUVA to assess if revenue growth can offset operating losses.
• Legal Risk: Monitor the outcome of the litigation with Commave Therapeutics regarding the AZSTARYS license, which is a key revenue source.
• Inventory Valuation: Review future inventory write-down risks given the $5.2 million charge already recognized in 2024.